Prostate cancer (2025 – CME) – online course
Description
Authors: J. Fütterer, S. Jenniskens and C. Overduin
Reviewers: F. H. Cornelis, D. Filippiadis, J.A. Guirola, R. Iezzi, A. Kovács, M. Szmygin and R. Uberoi.
This course corresponds to chapter 2.2.4.2 Percutaneous ablation of bone and soft tissue lesions in the European Curriculum and Syllabus for Interventional Radiology.
Abstract
Prostate cancer is the second most common cancer in men. It represents a major health burden in developed countries, particularly with a growing proportion of elderly men and widespread PSA screening programmes. Multiparametric magnetic resonance imaging (MRI) plays a central role in the diagnosis and detection of clinically significant prostate cancer. According to the EAU guideline, MRI-targeted biopsy is recommended for patients who are biopsy naïve as well as for those who had a negative systematic 12-core TRUS biopsy. Multiparametric MRI has also been shown to reduce the number of unnecessary biopsies in biopsy-naive patients and improves the accuracy of tumour grading and volume determinations in patients who had a prior negative systematic 12-core TRUS biopsy.
Low-risk prostate cancer is associated with a very favourable prognosis and can therefore be managed by active surveillance to reduce overtreatment and defer curative treatment to the point of evident disease progression. Definitive treatments (e.g., surgery or radiotherapy) are associated with treatment-related morbidity, including erectile, urinary, and bowel dysfunctions, contributing to decreased quality of life. In recent years, these key concerns have led to the development of focal therapy, as a less invasive, less side-effects for patients with intermediate-risk disease to be treated. Focal therapy is a tissue-preserving strategy that aims to reduce the morbidity related to whole gland treatment while retaining at least equivalent cancer control. Interventional radiologists use image-based manoeuvres to deliver several available forms of focal therapy. Focal therapy is becoming a mature treatment option for patients with localized prostate cancer.
Learning objectives
- Understand the clinical presentation of prostate cancer
- Know the role of imaging and biopsy
- Know the different IR treatment options for the treatment of (recurrent) prostate cancer and their outcomes
- Develop the ability to plan optimal treatment
- Identify the imaging appearance and endpoints during treatment, such as monitoring the progress of the ablation and determining when to conclude the procedure
- Learn techniques for minimizing the risk of complications during IR
- Recognize potential complications promptly
Further information
This course covers a basic level of IR knowledge and is designed for trainees, students or young consultants aiming to acquire essential knowledge or prepare for the EBIR exam. Thereby, it is tailored to the European Curriculum and Syllabus for Interventional Radiology and corresponds to chapter 2.2.5.3.3 Prostate cancer.
The format of the course is interactive and easy to use, including texts, graphics, videos and a quiz to support your learning. The course duration is around one and a half hours and is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to award 1.5 European CME credit (ECMEC). The CME accreditation for this course will expire on March 24, 2027. A non-CME accredited version of the course will remain available online.
The acquired CME Certificate will be available in the myCIRSE area under CIRSE Academy.
The enrolment period of this course is linked to the validity of the All-Access Pass.
Release date: March 2025
